In brief: Meditech, Psivida, Regenera, Mesoblast
Wednesday, 24 August, 2005
Cancer biopharma Meditech Research (ASX:MTR) has been offered a AUD$2.98 million AusIndustry Commercial Ready Grant over the next three years towards the development and commercialisation of its lead anti-cancer product HyCAMP, which is in Phase II clinical testing.
Meanwhile, Robert Stewart has taken over as Meditech's chairman. Prof Richard Fox will remain as a non-executive director and will continue to advise the company on clinical development and medical issues.
Perth-based nanotech Psivida (ASX:PSD) has raised US$4.2 million before costs via the private placement of 650,000 on American Depository Receipts to predominantly US investors at US$6.50 each. Each ADR represents 10 ordinary shares.
Perth's Regenera (ASX:RGA) has received its first licensing payment of AUD$1.3 million from Alcon Manufacturing in accordance with an exclusive global license granted by Regenera to Alcon in April 2005. The license involves a steroid product that is used during ocular surgery. Adult stem cell company Mesoblast (ASX:MSB) has entered into an agreement with an unnamed medical device company which will provide carrier materials for use in Mesoblast's preclinical trials.
Protein-based therapy helps the body remove harmful cells
Scientists have created a protein-based therapeutic tool that could change the way we treat...
Diabetes changes the structure of our hearts, study finds
Type 2 diabetes directly alters the heart's structure and energy systems, which explains why...
Beta blockers could halt triple negative breast cancer
Researchers have identified a molecular biomarker in triple negative breast cancer tumours which...
